Eiko Lifescience

Why is Eiko Lifesciences Ltd falling/rising?

As of 31-Aug, Eiko Lifesciences Ltd's stock price is at 47.18, down 1.69%, and has underperformed its sector. The stock has declined 2.58% over the past month and 14.30% year-to-date, indicating a bearish trend despite a rise in delivery volume.

As of 31-Aug, Eiko Lifesciences Ltd's stock price is falling, currently at 47.18, which reflects a decrease of 0.81 or 1.69%. The stock has underperformed its sector by 1.25% today and is trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past month, the stock has declined by 2.58%, while the benchmark Sensex has only fallen by 1.46%. Year-to-date, Eiko Lifesciences has experienced a significant drop of 14.30%, compared to a 9.70% decline in the Sensex. Additionally, despite a rise in delivery volume by 40.92% against the 5-day average, the overall performance remains weak, contributing to the stock's downward movement.

Who are in the management team of Eiko Lifescience?

The management team of Eiko Lifescience includes Chairman Laxmikant Kabra, Non-Executive Director Bhavesh Tanna, Independent Directors Rajkumar Baheti, Mandkar Patil, and Kajal Kothari, Whole-time Director Umesh More, and Company Secretary Chintan Doshi.

The management team of Eiko Lifescience includes the following individuals:<BR><BR>1. **Laxmikant Kabra** - Chairman & Non Executive Director<BR>2. **Bhavesh Dhirajlal Tanna** - Non-Executive & Non-Independent Director<BR>3. **Rajkumar K Baheti** - Independent Non-Executive Director<BR>4. **Mandkar Kamalakar Patil** - Independent Non-Executive Director<BR>5. **Kajal Dhanpatraj Kothari** - Independent Non-Executive Director<BR>6. **Umesh Ravindranath More** - Whole-time Director<BR>7. **Chintan Doshi** - Company Secretary & Compliance Officer<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Eiko Lifescience do?

Eiko Lifesciences Ltd is a manufacturer and exporter of specialty chemicals and pharma intermediates, operating in the Micro Cap market. As of June 2026, it reported net sales of 17 Cr and a net profit of 1 Cr, with a market cap of INR 70 Cr.

Overview:<BR>Eiko Lifesciences Ltd is a leading manufacturer, supplier, and exporter of Specialty Chemicals and Pharma Intermediates, operating within the Micro Cap market segment.<BR><BR>History:<BR>Eiko Lifesciences Ltd was originally incorporated on January 7, 1977, under the name Narendra Investments (Delhi) Limited. The company was renamed to Eiko Lifesciences Limited on June 24, 2021. The latest quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 17 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 70 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 14.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.07<BR>- Return on Equity: 6.54%<BR>- Price to Book: 1.03<BR><BR>Contact Details:<BR>Address: 1st Matru Chhaya Ground Floor, M Karve Road Naupada Thane Maharashtra : 400602<BR>Tel: 91-22-25390009/25438095<BR>Email: narendrainvestmentdelhi@gmail.com<BR>Website: http://www.eikolifesciences.com

Who are the peers of the Eiko Lifescience?

Eiko Lifescience's peers include Deep Polymers, Deepak Chemtex, Technichem Org., Alkali Metals, KKalpana Inds., Hardcast.& Waud, Kemistar Corp., Crestchem, and Ambani Orgochem. Eiko shows excellent growth and capital structure, with a 1-year return of -7.89%, better than Deepak Chemtex but worse than Hardcast.& Waud, which has the highest return at 11.35%.

Peers: The peers of Eiko Lifescience are Deep Polymers, Deepak Chemtex, Technichem Org., Alkali Metals, KKalpana Inds., Hardcast.& Waud, Kemistar Corp., Crestchem, and Ambani Orgochem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Deepak Chemtex and Crestchem, while Average management risk is found at Kemistar Corp. Below Average management risk is noted for Deep Polymers, Technichem Org., Eiko Lifescience, Alkali Metals, KKalpana Inds., Hardcast.& Waud, and Ambani Orgochem. Eiko Lifescience shows Excellent growth, alongside Hardcast.& Waud, while Good growth is seen at Deep Polymers and Crestchem. Below Average growth is present in Deepak Chemtex, Technichem Org., Alkali Metals, KKalpana Inds., and Kemistar Corp. Excellent capital structure is noted for Eiko Lifescience and Deepak Chemtex, while Good capital structure is found at Hardcast.& Waud, Crestchem, and Technichem Org. Average capital structure is observed at Deep Polymers and Kemistar Corp., and Below Average capital structure is noted for Alkali Metals and KKalpana Inds.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Hardcast.& Waud at 11.35%, while the lowest is Deepak Chemtex at -41.75%. Eiko Lifescience's 1-year return of -7.89% is better than Deepak Chemtex but worse than Hardcast.& Waud. Additionally, peers such as Deepak Chemtex, Technichem Org., KKalpana Inds., and Kemistar Corp. have negative six-month returns.

How big is Eiko Lifescience?

As of 31st August, Eiko Lifesciences Ltd has a market capitalization of 70.00 Cr, with net sales of 58.74 Cr and a net profit of 4.90 Cr reported in the latest four quarters. Shareholder's funds are 68.78 Cr, and total assets amount to 89.37 Cr as of March 2026.

As of 31st August, Eiko Lifesciences Ltd has a market capitalization of 70.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Eiko Lifesciences reported net sales of 58.74 Cr and a net profit of 4.90 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with shareholder's funds amounting to 68.78 Cr and total assets of 89.37 Cr.

Which are the latest news on Eiko Lifescience?

Should I buy, sell or hold Eiko Lifesciences Ltd?

Are Eiko Lifesciences Ltd latest results good or bad?

Eiko Lifesciences Ltd's latest results show strong revenue growth, with Q4 FY26 net sales up 53.09% quarter-on-quarter, but profitability concerns arise from a declining operating margin and low return on equity. Overall, while the revenue performance is impressive, challenges in profitability and capital efficiency temper the outlook.

Eiko Lifesciences Ltd's latest results present a mixed picture. On one hand, the company achieved significant revenue growth, with net sales for Q4 FY26 reaching ₹18.34 crores, which is a remarkable increase of 53.09% quarter-on-quarter and 62.73% year-on-year. This marks the highest quarterly revenue in the company's history, indicating strong demand in its specialty chemicals segment.<BR><BR>However, the profitability metrics raise concerns. While net profit increased to ₹1.30 crores, reflecting a 7.44% growth quarter-on-quarter and 23.81% year-on-year, the operating margin (excluding other income) fell to 12.43%, down from 15.69% in the previous quarter. This contraction of 327 basis points suggests that the company may be facing challenges in maintaining pricing power amidst rising costs or competitive pressures.<BR><BR>Additionally, the return on equity (ROE) stands at a low 5.36%, significantly below industry standards, which raises questions about the company's capital efficiency and ability to generate returns for shareholders. <BR><BR>In summary, while Eiko Lifesciences has demonstrated impressive revenue growth, the accompanying margin compression and weak return ratios indicate that the overall financial performance is tempered by significant challenges. Investors may need to weigh the strong top-line growth against the concerns regarding profitability and capital efficiency.

When is the next results date for Eiko Lifesciences Ltd?

The next results date for Eiko Lifesciences Ltd is 26 May 2026.

The next results date for Eiko Lifesciences Ltd is scheduled for 26 May 2026.

How has been the historical performance of Eiko Lifescience?

Eiko Lifescience has shown significant growth from March 2018 to March 2025, with net sales rising from 2.34 crore to 37.66 crore and profit after tax increasing from 0.20 crore to 2.18 crore, alongside a substantial rise in total assets. The company has improved operational efficiency, reflected in higher operating profit and earnings per share.

Answer:<BR>The historical performance of Eiko Lifescience shows significant growth in net sales and profitability over the years, particularly from March 2018 to March 2025.<BR><BR>Breakdown:<BR>Eiko Lifescience's net sales increased dramatically from 2.34 crore in March 2018 to 37.66 crore in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 2.34 crore to 37.66 crore during the same period. The company's total expenditure also grew, from 1.99 crore in March 2018 to 34.90 crore in March 2025, but the operating profit (PBDIT) improved from 0.41 crore to 3.48 crore, indicating enhanced operational efficiency. Profit before tax transitioned from a profit of 0.25 crore in March 2018 to a profit of 2.92 crore in March 2025, while profit after tax showed a similar positive trend, moving from 0.20 crore to 2.18 crore. The earnings per share (EPS) improved significantly from 0.51 in March 2018 to 1.53 in March 2025. On the balance sheet, total assets increased from 10.95 crore in March 2018 to 66.10 crore in March 2025, with total liabilities also rising from 10.95 crore to 66.10 crore. The company reported a net cash outflow of 1.00 crore in March 2025, with closing cash and cash equivalents at 11.00 crore, up from virtually none in previous years. Overall, Eiko Lifescience has demonstrated substantial growth in both revenue and profitability, alongside an increase in assets and liabilities over the years.

Is Eiko Lifescience overvalued or undervalued?

As of November 13, 2025, Eiko Lifescience is considered undervalued with an attractive valuation grade, featuring a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which positions it favorably compared to peers like Bajaj Finance and Bajaj Finserv, despite recent underperformance against the Sensex.

As of 13 November 2025, Eiko Lifescience's valuation grade has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued. Key ratios include a PE ratio of 31.29, an EV to EBITDA of 30.99, and a PEG ratio of 0.32, which suggests that the stock is relatively inexpensive compared to its growth prospects.<BR><BR>In comparison to its peers, Eiko Lifescience's PE ratio is lower than Bajaj Finance's 34.18 and significantly better than the life insurance sector's 11.18, which is categorized as very attractive. Additionally, while Bajaj Finserv is considered expensive with a PE of 33.91, Eiko's valuation appears more favorable. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year returns, the company's attractive valuation metrics suggest potential for future growth.

What is the technical trend for Eiko Lifescience?

As of May 23, 2025, Eiko Lifescience's technical trend is mildly bearish, with bearish signals from moving averages and Bollinger Bands, although the weekly MACD and KST indicate some mildly bullish momentum.

As of 23 May 2025, the technical trend for Eiko Lifescience has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands are bearish on both weekly and monthly time frames, and daily moving averages also reflect a bearish trend. The KST shows a mildly bullish signal on both weekly and monthly charts, and Dow Theory suggests a mildly bullish outlook on the weekly basis but no trend on the monthly. Overall, the current technical stance is mildly bearish, influenced primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals from MACD and KST on the weekly time frame.

Who are the top shareholders of the Eiko Lifescience?

The top shareholders of Eiko Lifescience are Lenus Finvest Private Limited with 17.01%, followed by 2b Black Bio LLP at 9.95%, while individual investors hold 44.38%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Eiko Lifescience include Lenus Finvest Private Limited, which holds the highest promoter stake at 17.01%. The highest public shareholder is 2b Black Bio LLP, with a holding of 9.95%. Additionally, individual investors collectively own 44.38% of the company. There are currently no institutional holdings or pledged promoter shares.

Has Eiko Lifescience declared dividend?

Eiko Lifesciences Ltd has declared a 2% dividend, amounting to 0.2 per share, but the dividend yield is 0%. Total returns have varied significantly, with a notable 252.7% increase over the 5-year period, despite negative returns in shorter time frames.

Eiko Lifesciences Ltd has declared a 2% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: 0.2<BR>- Ex-date: 20 Sep 17<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -21.94%, the dividend return was 0%, resulting in a total return of -21.94%.<BR><BR>For the 1-year period, the price return was 2.51%, the dividend return was 0%, leading to a total return of 2.51%.<BR><BR>Over the 2-year period, the price return was -26.43%, with a dividend return of 0%, resulting in a total return of -26.43%.<BR><BR>In the 3-year period, the price return was -8.45%, the dividend return was 0%, giving a total return of -8.45%.<BR><BR>For the 4-year period, the price return was -34.26%, with a dividend return of 0%, leading to a total return of -34.26%.<BR><BR>In the 5-year period, the price return was 252.7%, the dividend return was 0%, resulting in a total return of 252.7%.<BR><BR>Overall, Eiko Lifesciences Ltd has declared a dividend, but the dividend yield remains at 0%, indicating that the dividends have not contributed to returns in recent periods. The total returns over various periods show significant fluctuations, with a notable increase over the 5-year period despite negative returns in shorter time frames.